Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Free Cash Flow: 2011-2024

Historic Free Cash Flow for Mimedx Group (MDXG) over the last 14 years, with Dec 2024 value amounting to $65.4 million.

  • Mimedx Group's Free Cash Flow rose 49.77% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.8 million, marking a year-over-year increase of 19.81%. This contributed to the annual value of $65.4 million for FY2024, which is 98.62% up from last year.
  • According to the latest figures from FY2024, Mimedx Group's Free Cash Flow is $65.4 million, which was up 98.62% from $33.0 million recorded in FY2023.
  • In the past 5 years, Mimedx Group's Free Cash Flow registered a high of $65.4 million during FY2024, and its lowest value of -$34.5 million during FY2020.
  • For the 3-year period, Mimedx Group's Free Cash Flow averaged around $26.3 million, with its median value being $33.0 million (2023).
  • In the last 5 years, Mimedx Group's Free Cash Flow slumped by 48.24% in 2022 and then soared by 269.78% in 2023.
  • Mimedx Group's Free Cash Flow (Yearly) stood at -$34.5 million in 2020, then spiked by 62.04% to -$13.1 million in 2021, then plummeted by 48.24% to -$19.4 million in 2022, then spiked by 269.78% to $33.0 million in 2023, then soared by 98.62% to $65.4 million in 2024.